The efficacy, safety, and efficiency of the off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: protocol for a systematic review and meta-analysis

Detalhes bibliográficos
Autor(a) principal: Estarreja, João
Data de Publicação: 2023
Outros Autores: Mendes, Priscila, Silva, Carina, Camacho, Pedro, Mateus, Vanessa
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.21/16279
Resumo: FCT_UIDB/05608/2020. FCT_UIDP/05608/2020.
id RCAP_f61820530bf75958cc0015a939f4ca02
oai_identifier_str oai:repositorio.ipl.pt:10400.21/16279
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling The efficacy, safety, and efficiency of the off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: protocol for a systematic review and meta-analysisOphthalmologyAge-related macular degenerationBevacizumabDrug therapynAMDNeovascular age-related macular degenerationWet macular degenerationFCT_UIDB/05608/2020FCT_UIDP/05608/2020FCT_UIDB/05608/2020. FCT_UIDP/05608/2020.Background: Age-related macular degeneration (AMD) is recognized as the leading cause of vision loss in older people. Considering the phenomenon of aging societies worldwide, the prevalence of AMD is expected to increase gradually in the future. AMD can be divided into early, intermediate, and late stages, with the early and intermediate stages being mainly asymptomatic, and the late stage being classified as geographic atrophy, neovascular AMD, or both. Current pharmacological treatments for neovascular AMD include anti-vascular endothelial growth factors agents, such as ranibizumab, pegaptanib, and aflibercept. Additionally, it has been reported that the off-label use of intravitreally administered bevacizumab is effective. It is also lower cost than other agents, which makes it an interesting pharmacological approach. Objective: This review aims to evaluate the efficacy, safety, and efficiency of bevacizumab for the treatment of neovascular AMD. Methods: This review will only consider randomized controlled clinical trials that compare the use of bevacizumab with another pharmacological agent or placebo in patients aged 50 years and older who are diagnosed with vascular AMD. It will exclude studies that include participants diagnosed with polypoidal choroidal vasculopathy or retinal angiomatous proliferation. To identify and select relevant articles, we will develop a highly sensitive search strategy and apply it in MEDLINE via the PubMed platform. Upon selection of the studies and analysis of the titles, abstracts, and full texts, the results will be presented according to the Preferred Reporting Items of Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The analysis and extraction of the data will be performed by 2 independent reviewers. The risk of bias will be evaluated with the Critical Appraisal Skills Programme (CASP) checklist. Finally, the same reviewers will also perform a quality assessment of the included studies with the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) tool. Results: The search strategy, after the application of the inclusion and exclusion criteria, identified 15 randomized clinical trials, which are currently being analyzed. This project has no funding and it has been developed by a multidisciplinary research team of pharmacologists and orthoptists. The study was initiated in May 2021 and it is expected to conclude by the end of 2023. Conclusions: This review will provide a synthesis of current information and underlying evidence about the off-label use of bevacizumab in neovascular AMD. It will provide a clearer vision of a possible new pharmacological approach, as well as the most suitable treatment designs, for the treatment of neovascular AMD.JMIR PublicationsRCIPLEstarreja, JoãoMendes, PriscilaSilva, CarinaCamacho, PedroMateus, Vanessa2023-07-05T09:09:29Z2023-062023-06-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.21/16279engEstarreja J, Mendes P, Silva C, Camacho P, Mateus V. The efficacy, safety, and efficiency of the off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: protocol for a systematic review and meta-analysis. JMIR Res Protoc. 2023;12:e38658.10.2196/38658info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-08-03T10:14:45Zoai:repositorio.ipl.pt:10400.21/16279Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:23:50.699617Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv The efficacy, safety, and efficiency of the off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: protocol for a systematic review and meta-analysis
title The efficacy, safety, and efficiency of the off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: protocol for a systematic review and meta-analysis
spellingShingle The efficacy, safety, and efficiency of the off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: protocol for a systematic review and meta-analysis
Estarreja, João
Ophthalmology
Age-related macular degeneration
Bevacizumab
Drug therapy
nAMD
Neovascular age-related macular degeneration
Wet macular degeneration
FCT_UIDB/05608/2020
FCT_UIDP/05608/2020
title_short The efficacy, safety, and efficiency of the off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: protocol for a systematic review and meta-analysis
title_full The efficacy, safety, and efficiency of the off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: protocol for a systematic review and meta-analysis
title_fullStr The efficacy, safety, and efficiency of the off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: protocol for a systematic review and meta-analysis
title_full_unstemmed The efficacy, safety, and efficiency of the off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: protocol for a systematic review and meta-analysis
title_sort The efficacy, safety, and efficiency of the off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: protocol for a systematic review and meta-analysis
author Estarreja, João
author_facet Estarreja, João
Mendes, Priscila
Silva, Carina
Camacho, Pedro
Mateus, Vanessa
author_role author
author2 Mendes, Priscila
Silva, Carina
Camacho, Pedro
Mateus, Vanessa
author2_role author
author
author
author
dc.contributor.none.fl_str_mv RCIPL
dc.contributor.author.fl_str_mv Estarreja, João
Mendes, Priscila
Silva, Carina
Camacho, Pedro
Mateus, Vanessa
dc.subject.por.fl_str_mv Ophthalmology
Age-related macular degeneration
Bevacizumab
Drug therapy
nAMD
Neovascular age-related macular degeneration
Wet macular degeneration
FCT_UIDB/05608/2020
FCT_UIDP/05608/2020
topic Ophthalmology
Age-related macular degeneration
Bevacizumab
Drug therapy
nAMD
Neovascular age-related macular degeneration
Wet macular degeneration
FCT_UIDB/05608/2020
FCT_UIDP/05608/2020
description FCT_UIDB/05608/2020. FCT_UIDP/05608/2020.
publishDate 2023
dc.date.none.fl_str_mv 2023-07-05T09:09:29Z
2023-06
2023-06-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.21/16279
url http://hdl.handle.net/10400.21/16279
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Estarreja J, Mendes P, Silva C, Camacho P, Mateus V. The efficacy, safety, and efficiency of the off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: protocol for a systematic review and meta-analysis. JMIR Res Protoc. 2023;12:e38658.
10.2196/38658
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv JMIR Publications
publisher.none.fl_str_mv JMIR Publications
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799133510574800896

Registros relacionados